ClinicalTrials.gg
CompletedNCT01523301Updated Dec 18, 2015Results posted

Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients

A Phase 4 interventional study of Rotigotine and Placebo in Idiopathic Parkinson's Disease, sponsored by UCB Korea Co., Ltd.. Completed at 29 sites in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-12-18.

Sponsored by UCB Korea Co., Ltd. (part of UCB S.A.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
380
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.

Enrollment
6th of 42
380 · median 123
Started
2012
with 7 others
Phase 4
8 of 44
none open now
Registered
21st of 44
by date

Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 6th largest by enrollment of the 42 interventional ones that give a count, is one of 8 that started in 2012, is one of 8 in phase 4, and was the 21st registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:

About rotigotine

rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing rotigotine in Parkinson Disease, or all of them as a file.
02

Study summary

The purpose of this study was to show superiority of Rotigotine over placebo on improvement of depressive symptoms in subjects with idiopathic Parkinson's disease.

Read the detailed description

The study included a maximum 2-week Screening Period, a maximum 4-week Titration Period for early-stage Parkinson's disease or maximum 7-week Titration Period for advanced-stage Parkinson's disease, 8-week Maintenance Period, a maximum 6-day De-escalation Period for early-stage Parkinson's disease or maximum 12-day De-escalation Period for advanced-stage Parkinson's disease and 30-day Safety Follow-Up Period.

The maximum study durations for an individual subject with early-stage Parkinson's disease and with advanced-stage Parkinson's disease were 19 weeks and 23 weeks, respectively.

03

Conditions studied

  • Idiopathic Parkinson's Disease

Keywords

  • Rotigotine
  • Neupro
  • Depressive Symptom
  • Idiopathic Parkinson's disease
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects ≥ 20 years old
  • Subjects diagnosed with idiopathic Parkinson's disease (according to the United Kingdom Parkinson's Disease Society Brain Bank Diagnostic Criteria for Parkinson's disease) at modified Hoehn and Yahr Scale stages I-III; do not have motor fluctuations, dyskinesia, and have stable motor symptom at least 4 weeks prior to the Screening Visit as judged by the local investigator
  • Subject has a Beck Depression Inventory II (BDI-II) score ≥ 16 as evidenced by depression rating scale study in Parkinson's disease (Schrag A et al, 2007)
  • Subject has a (MMSE) score ≥ 24
  • If subject is taking Levodopa (L-DOPA) and derivatives, Monoamine Oxidase (MAO) B-inhibitors, anticholinergics agents, Catechol-O-Methyl Transferase (COMT) inhibitor or N-Methyl-D-Aspartate (NMDA) antagonist, he/she must have been on stable dose for at least 28 days prior to the Screening Visit
  • If subject is taking an antidepressant drug such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), bupropion, tricyclic antidepressants (TCAs), he/she must have been on a stable dose for at least 28 days prior to the Screening Visit and be maintained on that dose for the duration of the trial

Exclusion criteria

Exclusion Criteria:

  • Subject has any medical or psychiatric condition (ie, bipolar disorder, dementia, hallucinations or psychosis) that, in the opinion of the investigator, could jeopardize or would compromise the subject's ability to participate in this study
  • Subject has a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response ('Yes') to either Question 4 or Question 5 of the C-SSRS at Screening (Visit 1)
  • Current psychotherapy or behavior therapy while participating in this study
  • Subject has received electroconvulsive therapy within 12 weeks of the Screening Visit
  • Subject who has received dopamine agonists within 28 days of the Screening Visit
  • Subject who has received neuroleptics, methylphenidate, reserpine, alpha-methyldopa, metoclopramide, levosulpiride or amphetamine derivatives within 28 days of the Screening Visit
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
380 participants (actual)

Study arms

  • Experimental
    Rotigotine

    Rotigotine, daily doses, treatment group

    Drug: Rotigotine

  • Placebo comparator
    Placebo

    Placebo, daily doses, placebo group

    Drug: Placebo

Interventions

  • Transdermal Patch Content: 2 mg /24 h (10 cm\^2), 4 mg /24 h (20 cm\^2), 6 mg /24 h (30 cm\^2), 8 mg /24 h (40 cm\^2) * For early-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 2 mg/24 h to 8 mg/24 h) for a maximum 4-week Titration Period, then 8 week Maintenance period * For advanced-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 8 week Maintenance period

  • DrugPlacebo

    Transdermal Patch Size: 10 cm\^2, 20 cm\^2, 30 cm\^2, 40 cm\^2 Subjects randomized to placebo received matching placebo patches

06

What researchers measure

Primary outcomes

  1. Change From Baseline to the End of Maintenance Period in the Score of the Hamilton Depression Scale (HAM-D)

    The HAM-D consists of 17 items. Nine of the items are scored on a 5-point scale, ranging from 0 to 4. The remaining 8 items are scored on a 3-point scale, from 0 to 2. Therefore, the total score ranges between 0 to 52, with a cutoff score of 15/16 diagnosing major depressive disorder.

    Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 15)

Secondary outcomes

  1. Change From Baseline to the End of Maintenance Period in the Score of Beck Depression Inventory (BDI-II)

    The Beck Depression Inventory II (BDI-II) is a self-report instrument to measure Depression symptoms and severity. There are 21 items in the BDI-II. Scores of 0-13 are considered minimal depression; 14-19 indicates mild depression; 20-28 indicates moderate depression; and 29-63 indicates severe depression.

    Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 15)

  2. Change From Baseline to the End of Maintenance Period in the Score of Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living-ADL Subscale)

    The UPDRS Part II is a tool to measure Activities in Daily Living - it includes speech, salivation, swallowing, handwriting, cutting food and handling utensils, dressing, hygiene, turning in bed and adjusting clothes, falling (unrelated to freezing), freezing when walking, walking, tremor, and sensory complaints related to Parkinsonism. Each of the 13 questions is measured on a scale from 0 (normal) to 4 (severe). The total score of UPDRS part II ranges from 0 (normal) to 52 (severe).

    Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 15)

  3. Change From Baseline to the End of Maintenance Period in the Score of Unified Parkinson's Disease Rating Scale (UPDRS) Part III (Motor Subscale)

    Improvement of motor symptoms is measured by the change from Baseline in UPDRS Part III motor score. The UPDRS Part III is an accepted and validated scale for the assessment of motor function in Parkinson's disease. Each of the elements in the UPDRS Part III is measured on a scale of 0 to 4, where 0 is normal and 4 represents severe abnormalities. The total score of UPDRS part III ranges from 0 (normal) to 108 (severe abnormalities).

    Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 15)

  4. Change From Baseline to the End of Maintenance Period in the Combined Score of Unified Parkinson's Disease Rating Scale (UPDRS) Part II (ADL) Plus Part III (Motor Subscale)

    The combined score of UPDRS part II and UPDRS part III is the sum of the individual scores and threfore ranges from 0 (normal) to 160 (severe).

    Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 15)

  5. Change From Baseline to the End of Maintenance Period in the Score of Apathy Scale (AS)

    The AS is an abbreviated version of the Apathy Scale (AS). The AS consists of 14 items phrased as questions that are to be answered on a four-point Likert scale. It was developed specifically for patients with Parkinson Disease (PD). For questions 1-8, the scoring system is the following: not at all = 3 points; slightly = 2 points; some =1 point, a lot = 0 point. For questions 9-14: the scoring system is the following: not at all = 0 points; slightly = 1 point; some = 2 points; a lot = 3 points. Adding all scores provides the final score with a range from 0 to 42.

    Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 15)

  6. Change From Baseline to the End of Maintenance Period in the Score of Snaith-Hamilton Pleasure Scale (SHAPS)

    The SHAPS is a self-report instrument developed for the assessment of hedonic capacity. The sum of the 14 items scores ranges from 0 to 14. A higher score represents more anhedonic symptoms.

    Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 15)

07

Results

Posted Dec 18, 2015

Participant flow

This double-blind, randomized, multicenter, placebo-controlled, in-Patient study started recruiting in April 2012.

Participant flow — Overall Study
MilestoneRotigotinePlacebo
Started184196
Completed149164
Not completed3532
Withdrew: Adverse event2516
Withdrew: Lack of efficacy02
Withdrew: Protocol violation34
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject68
Withdrew: Other reason02

Outcome measures

PrimaryChange From Baseline to the End of Maintenance Period in the Score of the Hamilton Depression Scale (HAM-D)

The HAM-D consists of 17 items. Nine of the items are scored on a 5-point scale, ranging from 0 to 4. The remaining 8 items are scored on a 3-point scale, from 0 to 2. Therefore, the total score ranges between 0 to 52, with a cutoff score of 15/16 diagnosing major depressive disorder.

Time frame:
From Baseline (Week 0) to end of Maintenance Period (up to Week 15)
Reported as:
Least squares mean · units on a scale
Change From Baseline to the End of Maintenance Period in the Score of the Hamilton Depression Scale (HAM-D)
units on a scaleEfficacy Evaluable Set (Rotigotine Treated Subjects)Efficacy Evaluable Set (Placebo Treated Subjects)
Change From Baseline to the End of Maintenance Period in the Score of the Hamilton Depression Scale (HAM-D)-4.79 (-5.87 to -3.71)-3.68 (-4.68 to -2.67)
Statistical analysis
  • Efficacy Evaluable Set (Rotigotine Treated Subjects) vs Efficacy Evaluable Set (Placebo Treated Subjects) · ANCOVA · p = =0.1286 (The null hypothesis was assessed with a 2-sided test and not rejected at p≤0.05.) · Difference in ls mean: -1.12 · 95% CI -2.56 to 0.33
SecondaryChange From Baseline to the End of Maintenance Period in the Score of Beck Depression Inventory (BDI-II)

The Beck Depression Inventory II (BDI-II) is a self-report instrument to measure Depression symptoms and severity. There are 21 items in the BDI-II. Scores of 0-13 are considered minimal depression; 14-19 indicates mild depression; 20-28 indicates moderate depression; and 29-63 indicates severe depression.

Time frame:
From Baseline (Week 0) to end of Maintenance Period (up to Week 15)
Reported as:
Least squares mean · units on a scale
Change From Baseline to the End of Maintenance Period in the Score of Beck Depression Inventory (BDI-II)
units on a scaleEfficacy Evaluable Set (Rotigotine Treated Subjects)Efficacy Evaluable Set (Placebo Treated Subjects)
Change From Baseline to the End of Maintenance Period in the Score of Beck Depression Inventory (BDI-II)-5.87 (-7.39 to -4.34)-4.68 (-6.11 to -3.26)
SecondaryChange From Baseline to the End of Maintenance Period in the Score of Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living-ADL Subscale)

The UPDRS Part II is a tool to measure Activities in Daily Living - it includes speech, salivation, swallowing, handwriting, cutting food and handling utensils, dressing, hygiene, turning in bed and adjusting clothes, falling (unrelated to freezing), freezing when walking, walking, tremor, and sensory complaints related to Parkinsonism. Each of the 13 questions is measured on a scale from 0 (normal) to 4 (severe). The total score of UPDRS part II ranges from 0 (normal) to 52 (severe).

Time frame:
From Baseline (Week 0) to end of Maintenance Period (up to Week 15)
Reported as:
Least squares mean · units on a scale
Change From Baseline to the End of Maintenance Period in the Score of Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living-ADL Subscale)
units on a scaleEfficacy Evaluable Set (Rotigotine Treated Subjects)Efficacy Evaluable Set (Placebo Treated Subjects)
Change From Baseline to the End of Maintenance Period in the Score of Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living-ADL Subscale)-1.13 (-1.76 to -0.50)-0.10 (-0.69 to 0.49)
SecondaryChange From Baseline to the End of Maintenance Period in the Score of Unified Parkinson's Disease Rating Scale (UPDRS) Part III (Motor Subscale)

Improvement of motor symptoms is measured by the change from Baseline in UPDRS Part III motor score. The UPDRS Part III is an accepted and validated scale for the assessment of motor function in Parkinson's disease. Each of the elements in the UPDRS Part III is measured on a scale of 0 to 4, where 0 is normal and 4 represents severe abnormalities. The total score of UPDRS part III ranges from 0 (normal) to 108 (severe abnormalities).

Time frame:
From Baseline (Week 0) to end of Maintenance Period (up to Week 15)
Reported as:
Least squares mean · units on a scale
Change From Baseline to the End of Maintenance Period in the Score of Unified Parkinson's Disease Rating Scale (UPDRS) Part III (Motor Subscale)
units on a scaleEfficacy Evaluable Set (Rotigotine Treated Subjects)Efficacy Evaluable Set (Placebo Treated Subjects)
Change From Baseline to the End of Maintenance Period in the Score of Unified Parkinson's Disease Rating Scale (UPDRS) Part III (Motor Subscale)-3.07 (-4.28 to -1.86)-1.65 (-2.78 to -0.52)
SecondaryChange From Baseline to the End of Maintenance Period in the Combined Score of Unified Parkinson's Disease Rating Scale (UPDRS) Part II (ADL) Plus Part III (Motor Subscale)

The combined score of UPDRS part II and UPDRS part III is the sum of the individual scores and threfore ranges from 0 (normal) to 160 (severe).

Time frame:
From Baseline (Week 0) to end of Maintenance Period (up to Week 15)
Reported as:
Least squares mean · units on a scale
Change From Baseline to the End of Maintenance Period in the Combined Score of Unified Parkinson's Disease Rating Scale (UPDRS) Part II (ADL) Plus Part III (Motor Subscale)
units on a scaleEfficacy Evaluable Set (Rotigotine Treated Subjects)Efficacy Evaluable Set (Placebo Treated Subjects)
Change From Baseline to the End of Maintenance Period in the Combined Score of Unified Parkinson's Disease Rating Scale (UPDRS) Part II (ADL) Plus Part III (Motor Subscale)-4.20 (-5.79 to -2.62)-1.81 (-3.29 to -0.33)
SecondaryChange From Baseline to the End of Maintenance Period in the Score of Apathy Scale (AS)

The AS is an abbreviated version of the Apathy Scale (AS). The AS consists of 14 items phrased as questions that are to be answered on a four-point Likert scale. It was developed specifically for patients with Parkinson Disease (PD). For questions 1-8, the scoring system is the following: not at all = 3 points; slightly = 2 points; some =1 point, a lot = 0 point. For questions 9-14: the scoring system is the following: not at all = 0 points; slightly = 1 point; some = 2 points; a lot = 3 points. Adding all scores provides the final score with a range from 0 to 42.

Time frame:
From Baseline (Week 0) to end of Maintenance Period (up to Week 15)
Reported as:
Least squares mean · units on a scale
Change From Baseline to the End of Maintenance Period in the Score of Apathy Scale (AS)
units on a scaleEfficacy Evaluable Set (Rotigotine Treated Subjects)Efficacy Evaluable Set (Placebo Treated Subjects)
Change From Baseline to the End of Maintenance Period in the Score of Apathy Scale (AS)-1.93 (-2.83 to -1.04)-0.67 (-1.50 to 0.17)
SecondaryChange From Baseline to the End of Maintenance Period in the Score of Snaith-Hamilton Pleasure Scale (SHAPS)

The SHAPS is a self-report instrument developed for the assessment of hedonic capacity. The sum of the 14 items scores ranges from 0 to 14. A higher score represents more anhedonic symptoms.

Time frame:
From Baseline (Week 0) to end of Maintenance Period (up to Week 15)
Reported as:
Least squares mean · units on a scale
Change From Baseline to the End of Maintenance Period in the Score of Snaith-Hamilton Pleasure Scale (SHAPS)
units on a scaleEfficacy Evaluable Set (Rotigotine Treated Subjects)Efficacy Evaluable Set (Placebo Treated Subjects)
Change From Baseline to the End of Maintenance Period in the Score of Snaith-Hamilton Pleasure Scale (SHAPS)-0.82 (-1.28 to -0.37)-0.60 (-1.03 to -0.17)

Adverse events

Collected over Treatment-emergent Adverse Events (TEAE) were collected during the study, which began in April 2012 and concluded in October 2014.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rotigotine—6/184 (3.3%)112/184 (60.9%)
Placebo—14/196 (7.1%)91/196 (46.4%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventRotigotinePlacebo
Jaw fractureInjury, poisoning and procedural complications0/1842/196
SpondylolisthesisCongenital, familial and genetic disorders1/1840/196
HepatitisHepatobiliary disorders1/1840/196
JaundiceHepatobiliary disorders1/1840/196
Kidney transplant rejectionImmune system disorders1/1840/196
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/1840/196
MyalgiaMusculoskeletal and connective tissue disorders1/1840/196
OsteoarthritisMusculoskeletal and connective tissue disorders1/1840/196
DizzinessNervous system disorders1/1840/196
TremorNervous system disorders1/1840/196
Most frequent other events
Showing 10 of 12
Most frequent other events
EventRotigotinePlacebo
NauseaGastrointestinal disorders42/18415/196
DizzinessNervous system disorders28/18425/196
Suicidal ideationPsychiatric disorders21/18422/196
Application site pruritusGeneral disorders19/18410/196
HeadacheNervous system disorders19/18420/196
VomitingGastrointestinal disorders13/1842/196
InsomniaPsychiatric disorders13/1846/196
NasopharyngitisInfections and infestations7/18413/196
PruritusSkin and subcutaneous tissue disorders12/1842/196
Application site erythemaGeneral disorders11/1845/196

Baseline characteristics

Baseline Characteristics refer to the Randomized Set (RS), which consists of all randomized subjects.

Age, Continuous
Age, Continuous(years)RotigotinePlaceboTotal Title
Mean65.6 ± 8.964.9 ± 8.265.2 ± 8.5
Age, Customized
Age, Customized(participants)RotigotinePlaceboTotal Title
<=18 years000
>18-<65 years7688164
>=65 years108108216
Sex: Female, Male
Sex: Female, Male(Participants)RotigotinePlaceboTotal Title
Female96122218
Male8874162
Weight
Weight(kg)RotigotinePlaceboTotal Title
Mean61.54 ± 9.6862.24 ± 9.8461.90 ± 9.76
Height
Height(cm)RotigotinePlaceboTotal Title
Mean160.04 ± 8.41159.17 ± 8.14159.59 ± 8.27
08

Study locations

29 sites
  • 03
    Ansan, Korea, Republic of
  • 19
    Anyang, Korea, Republic of
  • 08
    Busan, Korea, Republic of
  • 26
    Busan, Korea, Republic of
  • 23
    Chungbuk, Korea, Republic of
  • 04
    Daegu, Korea, Republic of
  • 05
    Daegu, Korea, Republic of
  • 16
    Daejon, Korea, Republic of
  • 28
    Goyang, Korea, Republic of
  • 24
    Gwangju, Korea, Republic of
  • 29
    Gwangju, Korea, Republic of
  • 11
    Gyeonggi-Do, Korea, Republic of
  • 15
    Jinju, Korea, Republic of
  • 01
    Seoul, Korea, Republic of
  • 02
    Seoul, Korea, Republic of
  • 06
    Seoul, Korea, Republic of
  • 07
    Seoul, Korea, Republic of
  • 09
    Seoul, Korea, Republic of
  • 10
    Seoul, Korea, Republic of
  • 12
    Seoul, Korea, Republic of
  • 13
    Seoul, Korea, Republic of
  • 14
    Seoul, Korea, Republic of
  • 17
    Seoul, Korea, Republic of
  • 18
    Seoul, Korea, Republic of
  • 20
    Seoul, Korea, Republic of
  • 21
    Seoul, Korea, Republic of
  • 22
    Seoul, Korea, Republic of
  • 27
    Seoul, Korea, Republic of
  • 25
    Yangsan, Korea, Republic of
09

References and documents

Publications

  • Chung SJ, Asgharnejad M, Bauer L, Ramirez F, Jeon B. Evaluation of rotigotine transdermal patch for the treatment of depressive symptoms in patients with Parkinson's disease. Expert Opin Pharmacother. 2016 Aug;17(11):1453-61. doi: 10.1080/14656566.2016.1202917. Epub 2016 Jul 7. PubMed 27322571 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2015, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2012
First posted
Feb 1, 2012
Start
Apr 2012
Primary completionActual
Oct 2014
CompletionActual
Oct 2014
Results first posted
Dec 18, 2015
Last update
Dec 18, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01523301
Responsible party
Sponsor
First posted
Feb 1, 2012
Start date
Apr 2012
Primary completion
Oct 2014
Completion
Oct 2014
Results posted
Dec 18, 2015
Last update
Dec 18, 2015

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion